| Characteristic | No. (%) of respondents* | ||
|---|---|---|---|
| Total n = 166 | Did not prescribe cannabinoids n = 127 | Prescribed cannabinoids n = 38 | |
| Sex | |||
| Male | 77 (46.4) | 59 (46.5) | 18 (47.4) |
| Female | 89 (53.6) | 68 (53.5) | 20 (52.6) |
| Years of practice | n = 162 | n = 123 | |
| ≤ 5 | 30 (18.5) | 24 (19.5) | 6 (15.8) |
| 6–10 | 20 (12.3) | 14 (11.4) | 6 (15.8) |
| 11–20 | 50 (30.9) | 41 (33.3) | 9 (23.7) |
| ≥ 21 | 62 (38.3) | 44 (35.8) | 17 (44.7) |
| Medical specialty | n = 127 | ||
| Family physician/general practitioner | 93 (56.0) | 60 (47.2) | 32 (84.2) |
| Other specialty | 73 (44.0) | 67 (52.8) | 6 (15.8) |
| Work environment frequented in past year† | n = 163 | n = 124 | |
| Hospital (excluding emergency department) | 87 (53.4) | 74 (59.7) | 13 (34.2) |
| Family medicine group or unit | 43 (26.4) | 25 (20.2) | 17 (44.7) |
| Emergency department | 35 (21.5) | 26 (21.0) | 9 (23.7) |
| Private medical office | 21 (12.9) | 13 (10.5) | 8 (21.1) |
| Environment offering palliative care | 11 (6.7) | 4 (3.2) | 7 (18.4) |
| Local community services centre | 12 (7.4) | 8 (6.5) | 4 (10.5) |
| Long-term care facility | 8 (4.9) | 3 (2.4) | 5 (13.2) |
| Abitibi-Témiscamingue health and social services agency | 6 (3.7) | 5 (4.0) | 1 (2.6) |
| Other | 5 (3.1) | 4 (3.2) | 1 (2.6) |
| % of medical practice dedicated to seeing patients in past year | n = 160 | n = 121 | |
| Mean ± SD | 82.4 ± 24.2 | 80.3 ± 28.4 | 86.3 ± 14.0 |
| Median | 90 | 90 | 90 |
| % of medical practice dedicated to seeing patients in past year | n = 160 | n = 121 | |
| < 50% | 13 (8.1) | 12 (9.9) | 1 (2.6) |
| ≥ 50% | 147 (91.9) | 109 (90.1) | 37 (97.4) |
| No. of patients seen each week in medical practice | n = 163 | n = 124 | |
| Mean ± SD | 58.4 ± 37.2 | 52.3 ± 33.1 | 73.6 ± 47.3 |
| Median | 50 | 50 | 60 |
| Perception of CNCP prevalence among clientele | n = 159 | n = 120 | |
| Mean ± SD | 22.1 ± 17.4 | 19.7 ± 15.1 | 28.6 ± 22.2 |
| Median | 20 | 20 | 20 |
| Perception of CNCP prevalence among clientele | n = 159 | n = 120 | |
| < 50% of patients | 146 (91.8) | 111 (92.5) | 34 (89.5) |
| ≥ 50% of patients | 13 (8.2) | 9 (7.5) | 4 (10.5) |
| % of CME activities about CNCP and its treatment in past year | n = 159 | n = 121 | n = 37 |
| 0 | 54 (34.0) | 51 (42.1) | 3 (8.1) |
| 1–10 | 71 (44.7) | 50 (41.3) | 21 (56.8) |
| 11–20 | 28 (17.6) | 18 (14.9) | 9 (24.3) |
| 21–30 | 4 (2.5) | 1 (0.8) | 3 (8.1) |
| 31–40 | 2 (1.3) | 1 (0.8) | 1 (2.7) |
| % of CME activities about cannabinoids in past year | n = 159 | n = 120 | |
| 0 | 126 (79.2) | 104 (86.7) | 22 (57.9) |
| 1–20 | 33 (20.8) | 16 (13.3) | 16 (42.1) |
| Level of comfort with prescribing cannabinoids for CNCP (10-point scale), mean ± SD | n = 155 2.5 ± 2.8 | n = 116 1.4 ± 1.9 | 5.9 ± 2.5 |
Note: CME = continuing medical education, CNCP = chronic noncancer pain; SD = standard deviation. *Unless stated otherwise. Proportion of missing data ≤ 4.2%. †Categories are not mutually exclusive; a physician could be working in more than 1 environment.